SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

Citation
Noergaard C, Torp-Pedersen C, Vestergaard P, et al. Eur Heart J 2019;40(Suppl 1):ehz747.0054.